Vibrio cholerae O139 persists in Dhaka, Bangladesh since 1993.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
14
05
2021
accepted:
10
08
2021
revised:
15
09
2021
pubmed:
3
9
2021
medline:
15
12
2021
entrez:
2
9
2021
Statut:
epublish
Résumé
After a multi-country Asian outbreak of cholera due to Vibrio cholerae serogroup O139 which started in 1992, it is rarely detected from any country in Asia and has not been detected from patients in Africa. We extracted surveillance data from the Dhaka and Matlab Hospitals of International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) to review trends in isolation of Vibrio cholerae O139 in Bangladesh. Data from the Dhaka Hospital is a 2% sample of > 100,000 diarrhoeal patients treated annually. Data from the Matlab Hospital includes all diarrhoeal patients who hail from the villages included in the Matlab Health and Demographic Surveillance System. Vibrio cholerae O139 was first isolated in Dhaka in 1993 and had been isolated every year since then except for a gap between 2005 and 2008. An average of thirteen isolates was detected annually from the Dhaka Hospital during the last ten years, yielding an estimated 650 cases annually at this hospital. During the last ten years, cases due to serogroup O139 represented 0.47% of all cholera cases; the others being due to serogroup O1. No cases with serogroup O139 were identified at Matlab since 2006. Clinical signs and symptoms of cholera due to serogroup O139 were similar to cases due to serogroup O1 though more of the O139 cases were not dehydrated. Most isolates of O139 remained sensitive to tetracycline, ciprofloxacin, and azithromycin, but they became resistant to erythromycin starting in 2009. Cholera due to Vibrio cholerae serogroup O139 continues to cause typical cholera in Dhaka, Bangladesh.
Sections du résumé
BACKGROUND
After a multi-country Asian outbreak of cholera due to Vibrio cholerae serogroup O139 which started in 1992, it is rarely detected from any country in Asia and has not been detected from patients in Africa.
METHODOLOGY/PRINCIPAL FINDINGS
We extracted surveillance data from the Dhaka and Matlab Hospitals of International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) to review trends in isolation of Vibrio cholerae O139 in Bangladesh. Data from the Dhaka Hospital is a 2% sample of > 100,000 diarrhoeal patients treated annually. Data from the Matlab Hospital includes all diarrhoeal patients who hail from the villages included in the Matlab Health and Demographic Surveillance System. Vibrio cholerae O139 was first isolated in Dhaka in 1993 and had been isolated every year since then except for a gap between 2005 and 2008. An average of thirteen isolates was detected annually from the Dhaka Hospital during the last ten years, yielding an estimated 650 cases annually at this hospital. During the last ten years, cases due to serogroup O139 represented 0.47% of all cholera cases; the others being due to serogroup O1. No cases with serogroup O139 were identified at Matlab since 2006. Clinical signs and symptoms of cholera due to serogroup O139 were similar to cases due to serogroup O1 though more of the O139 cases were not dehydrated. Most isolates of O139 remained sensitive to tetracycline, ciprofloxacin, and azithromycin, but they became resistant to erythromycin starting in 2009.
CONCLUSIONS/SIGNIFICANCE
Cholera due to Vibrio cholerae serogroup O139 continues to cause typical cholera in Dhaka, Bangladesh.
Identifiants
pubmed: 34473699
doi: 10.1371/journal.pntd.0009721
pii: PNTD-D-21-00698
pmc: PMC8443037
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009721Subventions
Organisme : NIAID NIH HHS
ID : R01 AI123422
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Trop Med Hyg. 2021 Apr 5;:
pubmed: 33819171
Lancet Infect Dis. 2018 Jun;18(6):666-674
pubmed: 29550406
J Clin Microbiol. 2019 Apr 26;57(5):
pubmed: 30814268
Epidemiol Infect. 2016 Apr;144(5):927-39
pubmed: 26391481
J Clin Microbiol. 2014 Apr;52(4):1146-52
pubmed: 24452176
Int J Epidemiol. 2017 Jun 1;46(3):809-816
pubmed: 28637343
Vaccine. 2020 Feb 29;38 Suppl 1:A31-A40
pubmed: 31395455
Emerg Infect Dis. 2007 Jan;13(1):18-24
pubmed: 17370511
Infect Immun. 1994 Apr;62(4):1504-6
pubmed: 7510671
Sci Rep. 2019 Apr 10;9(1):5865
pubmed: 30971707
Lancet. 2004 Jan 17;363(9404):223-33
pubmed: 14738797
Epidemiology. 2010 Sep;21(5):706-10
pubmed: 20562706
BMC Public Health. 2019 Sep 13;19(1):1264
pubmed: 31519163
Emerg Infect Dis. 2016 Mar;22(3):410-6
pubmed: 26886511
Emerg Infect Dis. 2019 May;25(5):856-864
pubmed: 31002075
Wkly Epidemiol Rec. 2015 Oct 2;90(40):517-28
pubmed: 26433979
Lancet. 1993 Aug 14;342(8868):387-90
pubmed: 8101899
Lancet. 2017 Sep 23;390(10101):1539-1549
pubmed: 28302312
Jpn J Infect Dis. 2018 Mar 22;71(2):99-103
pubmed: 29279443
Am J Epidemiol. 1982 Dec;116(6):959-70
pubmed: 7148820
PLoS Negl Trop Dis. 2015 Nov 12;9(11):e0004183
pubmed: 26562418
PLoS Negl Trop Dis. 2015 Jun 04;9(6):e0003832
pubmed: 26043000